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animals. CVVH-related sepsis-protection led to a significantImpact of different modalities of continuous venovenous hemo-
attenuation of histological injury in lungs and kidneys. “Pro-filtration on sepsis-induced alterations in experimental pan-
phylactic” CVVH prevented histological changes more effec-creatitis.
tively than “late” CVVH.Background. Continuous venovenous hemofiltration (CVVH)
Conclusions. CVVH offers a therapeutic option for support-is assumed to attenuate systemic complications in septic dis-
eases. The impact of different treatment intensities of CVVH ive treatment in severe pancreatitis. The efficiency of CVVH
on immunologic and systemic alterations in experimental pan- is associated with the duration of filter use and cumulative
creatitis was evaluated. plasma turnover. Since CVVH may lead to sepsis-protection
Methods. Eighty-four minipigs were allocated either to an and long-term survival, further evaluation in controlled, clinical
untreated control group (group 1) or to one of six treatment trials is warranted.
groups (groups 2 to 7) that underwent CVVH in different
modalities: (1): “late” CVVH, started after a decline of total
peripheral resistance of 30% versus “prophylactic” CVVH
The excessive activation of inflammatory mediator cas-started immediately after the induction of pancreatitis; (2) no
change of hemofilters versus a periodic change of filters every cades during acute, severe pancreatitis is assumed to be
12 hours; (3) low-volume CVVH with a filtrate turnover of a major cause of multiple organ dysfunction, which is
20 mL/kg body weight (BW)/h versus high-volume CVVH still associated with considerable mortality. Nonselective(100 mL/kg/h). Pancreatitis was induced by intraductal injec-
elimination of pancreatitis-related mediators was sug-tion of sodium-taurocholate (3%, 1 mL/kg BW) and enteroki-
gested as a preventative measure against the devastatingnase (2 U/kg BW). We focused on the occurrence of sepsis,
serum cytokines, down-regulation of major histocompatibility systemic complications after the onset of the disease. This
complex II (MHC II) and the endotoxin receptor CD14 expres- includes continuous venovenous hemofiltration (CVVH),
sion, bacterial translocation/endotoxemia, and pulmonary and which has been shown to be of considerable benefit forrenal histologic alterations.
the treatment of multiple organ dysfunction secondaryResults. CVVH delayed or definitively prevented the occur-
to sepsis [1–5].rence of sepsis. Pancreatitis was associated with a tremendous
initial tumor necrosis factor- (TNF-) response prior to a Our earlier study showed the benefits of CVVH in a
return to near baseline levels in the late course of sepsis. Endo- model of highly lethal necrotizing pancreatitis. Although
toxin hyporesponsiveness, suggested by the dissociation of de-
CVVH significantly prolonged survival time, it failed tocreasing TNF- levels and increasing endotoxemia in end-stage
result in definitive survival due to the severity of thesepsis, was favorably influenced by CVVH. Down-regulation
of MHC II and CD14 expression was prevented in non-septic model [6]. In the present study, we established an experi-
mental model that is characterized by the development
of pancreatitis-induced sepsis. This setting resembles the
Key words: hemofiltration, pancreatogenic sepsis, organ failure, im-
clinical situation in human acute pancreatitis better thanmunology, inflammation, multiple organ dysfunction, necrotizing pan-
creatitis. the former models of experimental pancreatitis.
In several clinical and experimental studies the ability
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of CVVH on sepsis-associated, pathologic findings that Induction of pancreatitis and experimental protocol
are not directly related to renal function. This is of partic- Pancreatitis was induced by pressure controlled, intra-
ular interest because the final pathway of pancreatitis- ductal injection of sodium-taurocholate (3%, 1 mL/kg
induced sepsis shares many characteristics with other BW; Sigma Co., Deisenhofen, Germany) and enteroki-
septic diseases, which include systemic histopathological nase (2 U/kg BW; Sigma Co.). Control animals (N 
abnormalities [8–11], the excessive release of pro- and 12; group 1) underwent the spontaneous course of the
anti-inflammatory cytokines [12–15], and leukocyte im- disease without any treatment. In six treatment groups,
munophenotypical alterations [16]. The present study the following modalities of CVVH were applied:
therefore investigated whether CVVH, performed in dif-
Group 2 (N 12): “Late” CVVH, defined as a begin-ferent treatment intensities, would result in protection
ning of CVVH after hemodynamic impairment (declinefrom these derangements. We focused in particular on
of total peripheral resistance to 30% below baseline val-the interaction of CVVH with serum levels of pro- and
ues) in a low volume mode (20 mL/kg BW/h) and withoutanti-inflammatory cytokines, histologic abnormalities in
change of hemofilterslungs and kidneys, bacterial translocation/endotoxemia,
Group 3 (N  12): “Prophylactic” CVVH started im-and immunodepression evidenced by leukocyte immu-
mediately after the induction of pancreatitis, low filtra-nophenotypical alterations.
tion rate, no filter change
Group 4 (N  12): “Late” low-volume CVVH with
METHODS filter change (12 hour intervals)
Group 5 (N 12): “Prophylactic” low-volume CVVHThe study was approved by the Ethical Committee of
with filter changethe Hamburg Federal Board of Veterinary Medicine and
Group 6 (N  12): “Late” high-volume CVVH (100Animal Care. Experiments were performed using mini-
mL/kg BW/h) with filter changepigs (Ellegard Co., Dalmose, Denmark) of either sex
Group 7 (N 12): “Prophylactic” high-volume CVVHweighing 31.2  3.4 kg with a median age of 15 months
with filter change(range 13 to 18 months old).
After a maximal observation period of 60 hours, ani-
Anesthesia and surgical preparation mals were sacrificed.
Anesthesia, instrumentation and surgical preparation
Sepsisof the animals were performed as previously described
[6]. Anesthesia was performed by continuous application In accordance with established clinical criteria [17, 18],
of propofol (6 mg/kg/h), and fentanyl (10 g/kg/h). After sepsis was assumed when bacteremia proven in blood
instrumentation of the animals by arterial and pulmonary cultures was associated with at least two of the following
catheters, mean arterial blood pressure (MAP), central signs: (1) body temperature 38.5C or 36C in con-
venous pressure (CVP), and heart rate (HR) were moni- trols and changes of 1.5C compared to baseline in
tored continuously. Total peripheral resistance (TPR), treatment groups, respectively, since preliminary experi-
cardiac output and cardiac index (CI) were determined ments revealed a median decline of body temperature
every 30 minutes. After laparotomy, the pancreatic duct by CVVH of 1.6C (1.1 to 1.9, N  8); (2) heart rate
was cannulated by a 5 F umbilical vein catheter. Two 120 beats/min; or (3) leukocytosis (12.000 cells/mm3)
drainages were placed in the abdomen for sampling ab- or leukopenia (4.000 cells/mm3).
dominal secretions for microbiologic analysis.
C-reactive protein, trypsinogen activation peptides,
Hemofiltration and white blood cells
Zero-balanced venovenous CVVH was performed in Plasma C-reactive protein (CRP) levels were assessed
a pre-dilution mode using a polyacrylnitrile membrane with an enzyme-linked immunosorbent assay (ELISA)
(AN 69S, Prisma M 60; Hospal Medizintechnik, Nu- as recently described [19]. Urinary trypsinogen activa-
remberg, Germany) connected to a continuous blood tion peptide (TAP) measurements also were performed
pump (Prisma; Hospal Medizintechnik). Ultrafiltrate with an ELISA (Biotrin, Sinsheim, Germany). White
rates were 20 mL/h/kg body weight (BW) in groups 2 to blood cell (WBC) counts were performed using a Coulter
5, and 100 mL/h/kg in groups 6 and 7, respectively. To Counter (Coulter Electronics, Hialeah, FL, USA).
obtain information about the elimination of tumor ne-
Cytokinescrosis factor- (TNF-), interleukin-10 (IL-10), and
transforming growth factor-1 (TGF-1), sieving coeffi- Cytokines were assessed in serum (pre- and post-filter)
and hemofiltrate. The concentrations of TNF- (Endo-cients (SC) were calculated as: SC 2Cf/(Ci	Co), where
Cf is the concentration in the hemofiltrate, Ci is the “in- gen, Inc., Eching, Germany), and IL-10 (BioSource In-
ternational, Inc., Camarillo, CA, USA) were measuredflow” (prefilter), and Co is the “outflow” (postfilter) lines.
Yekebas et al: Hemofiltration in pancreatogenic sepsis1808
Table 1. Histopathological scoring criteria (pancreas)
Parameter Findings Score points
Edema Absent 0
Diffuse expansion of interlobar septa 1
Same as 1 	 diffuse expansion of interlobular septa 2
Same as 2 	 diffuse expansion of interacinar septa 3
Same as 3 	 diffuse expansion of intercellullar septa 4
Acinar necrosis Absent 0
Diffuse occurrence of 1–4 necrotic cells/HPF 1
Diffuse occurrence of 5–10 necrotic cells/HPF 2
Diffuse occurrence of 11–16 necrotic cells/HPF 3
16 necrotic cells/HPF (extensive confluent necrosis) 4
Hemorrhage/fat necrosis Absent 0
2 foci 1
4 foci 2
6 foci 3

8 foci 4
Inflammation/perivascular infiltrate 0–5 intralobular or perivascular leukocytes/HPF 0
6–10 intralobular or perivascular leukocytes/HPF 1
11–20 intralobular or perivascular leukocytes/HPF 2
21–30 intralobular or perivascular leukocytes/HPF 3
31 intralobular or perivascular leukocytes/HPF/micro-abscesses 4
HPF is high power field. Maximal damage is 16 points.
Table 2. Histopathological scoring criteria (lungs, kidneys)
Parameters
Organ Score Hyaline membranes Microthrombi Edema Interstitial infiltrates Atelectasis Hemorrhage
Lungs 0 Absent Absent Absent Absent Absent Absent
1 Discrete Few in small vessels Discrete Discrete Small foci Small foci
2 Moderate Some Moderate Moderate Larger foci Larger foci
3 Severe Many, larger vessels Severe Severe Diffuse Diffuse
Tubular damage Glomerular damage Microthrombi
Kidneys 0 Absent Absent Absent
1 Diffuse dilatation, focal brush border defects Endothelial swelling Few
2 Diffuse brush border defects, focal tubular necrosis Glomerular edema Some
3 Diffuse tubular necrosis Glomerular fibrinoid necrosis Many
In case of score point deviation in different organ regions, the average from the respective score sum was calculated.
by swine-specific ELISA kits. TGF-1, known to show sections from kidneys and lungs were stained with H&E
and periodic acid-Schiff (PAS; 3 sections/kidney), andhigh homology between the human and porcine protein
[20], was detected using a human ELISA (Quantikine; H&E and Masson’s trichome (2 sections/lung area), re-
spectively, and scored for several variables (Table 2). InR&D Systems, Wiesbaden, Germany). Cross-reactiv-
ity between human and recombinant porcine TGF-1 case of score point deviation in different organ regions,
the mean from the respective score sum was calculated.assessed in preliminary experiments was 97%.
Histopathologic analysis Bacterial translocation/endotoxemia
Processing of swabs for microbiologic analysis and dif-Non-survivors or survivors killed by a lethal dose of
pentobarbital (200 mg/kg BW intravenously) underwent ferentiation of isolates were performed using standard
techniques. The following subsets were classified as positiveimmediate laparotomy and sternotomy. The entire pan-
creas, both kidneys, and specimens from the right upper, or negative: (1) Gram-negative, endotoxin containing En-
terobacteriaceae/non-fermentative rods (including Esche-medium and lower lung lobes were removed and fixed
in 10% formalin. After dividing the pancreas into the richia coli, Proteus mirabilis, Klebsiella pneumoniaea);
(2) Gram-positive cocci; and (3) Gram-negative/Gram-pancreatic head, body, and tail, respectively, and embed-
ding each in paraffin, sections through each of the areas positive anaerobes. To determine endotoxin (LPS) levels
in plasma, blood samples were drawn using pyrogen-freewere stained with hematoxylin and eosin (H&E). The
scoring of the pancreas was performed according to an tubes (Endo Tube ET; Chromogenix, Moelndal, Sweden)
and immediately centrifuged (3000 rpm for 15 min). Theestablished classification (Table 1) [21]. Wedge-shaped
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Table 3. Cardiac index (CI), and total peripheral resistance (TPR) during pancreatitis
Parameter Group Baseline 24 hours 36 hours 48 hours 60 hours
CI L/min · m2 1 4.21.1 9.32.2b 2.22.8b — —
2 4.01.5 6.01.8b,c 7.92.1a,c 2.72.0b —
3 4.51.6 6.62.1b,c 10.72.6b,c 2.22.5b —
4 4.61.3 6.72.9b,c 5.92.3a,c 3.42.6a 2.1 (N  1)
5 4.41.0 5.51.7a,c 5.42.0a,c 3.22.8 2.91.1b
6 3.91.2 6.32.1b,c 5.52.2a,c 6.12.7b,d–g 5.23.2a,f,g
7 4.31.3 5.21.5c,e 5.02.4c 5.63.0b,d–g 5.73.4a,f,g
TPR dyn · sec · cm5 1 1725402 612321b 492245b — —
2 1923342 1489375a,c 1182430a,c 643321b —
3 1643298 1827359c 792364b–d 521243b —
4 1942295 1673273c 1495462a,c–e 848429b 740 (N  1)
5 1756341 1582349c 1420490a,c–e 938314b,d,e 692212b
6 1815392 1592304c 1631481c–e 1521458a,d–g 1161517b,g
7 1832364 1628386c 1581399c–e 1394529a,d–g 1274485b,g
Data are means  SD. Groups are defined as: group 1, controls; group 2, ‘late’ beginning of low-volume CVVH with a filtration rate of 20 mL/kg BW/h but
without a change of hemofilters; group 3, ‘prophylactic’ low-volume CVVH without filter change; group 4, ‘late’ low-volume CVVH, with filter change every 12
hours; group 5, ‘prophylactic’ low-volume CVVH, filter change; group 6, ‘late’ high-volume CVVH with a filtration rate of 100 mL/kg BW/h, filter change; group 7,
‘prophylactic’ high-volume CVVH, filter change.
a P  0.05 and b P  0.01 vs. baseline values
c P  0.05 vs. the respective value in controls
d P  0.05 vs. group 2
e P  0.05 vs. group 3
f P  0.05 vs. group 4
g P  0.05 vs. group 5
supernatants were analyzed with the limulus amebocyte Statistics
lysate test (LAL Plasma Endotoxin Coatest, Chromo- Data are reported as means  standard deviation
genix). To assess whether lipopolysaccharide (LPS) was (SD). Survival times were calculated by the Kaplan-
able to pass the hemofilters, in preliminary experiments Meier analysis and compared by the log-rank test. Hemo-
(N 4) purified LPS (LPS from Salmonella abortus equi; dynamic parameters were evaluated by one-way analysis
Sigma Co.) was injected intravenously (10 g/kg). After- of variance (ANOVA) followed by the Student-New-
wards, blood samples from the in- and outflow lines of man-Keuls test for multiple comparison. For evaluation
of cytokine levels ANOVA followed by the Scheffe´ testthe extracorporeal circuit as well as hemofiltrate were
was performed. Bacteriologic findings were comparedtaken and subjected to immediate analysis.
using Fisher’s exact test. Categorical variables (histologic
scores) were analyzed using the modified ANOVA forMonitoring of altered leukocyte immunophenotypes
discrete data. Correlation analysis was performed usingby flow cytometric analysis for monoclonal antibodies
the Pearson correlation method. A P value 0.05 wasand conjugates
considered statistically significant.Anti-major histocompatibility complex (MHC) class II
[monoclonal antibody (mAb) MSA3; Dr. Saalmu¨ller,
Tu¨bingen, Germany] showing homology to human lym- RESULTS
phocyte antigen-DR (HLA-DR) [22] was used to assess Survival and hemodynamics
monocyte MHC II expression, and anti-CD14 (My 4;
The spontaneous course of pancreatitis was character-
Coulter Immunotech Diagnostics, Krefeld, Germany) was ized by an early-phase hyperdynamic response indicated
used to detect monocyte endotoxin receptor expression. by increases of cardiac index, heart rate, and body tem-
Staining of cells for two-color flow cytometric analysis perature, and decreases of mean arterial pressure, and
was performed in a two-step procedure: (1) incubation total peripheral resistance (Table 3; HR, MAP, and BT
of whole peripheral blood (100 L) with the respective data not shown). This initial hyperdynamic phase was
primary antibodies (50 L); (2) incubation with the re- followed by macrocirculatory instability with progressive
spective isotype-specific conjugates. Cells were shielded cardiac insufficiency indicated by a decrease of cardiac
from light at 4C before analysis. A four decade, flow cy- index. In treatment groups undergoing “late” CVVH
tometer with a 1024-channel, logarithmic amplifier (FACS- (groups 2, 4, and 6), animals had to be connected to
Calibur; Becton Dickinson, Heidelberg, Germany) was CVVH after a median of 16.1 hours (range 12.3 to 19.9
used. Measurements were run after 25,000 cells had been hours). Depending on the intensity of CVVH, the occur-
rence of hemodynamic impairment and elevation of bodycounted by the detector.
Yekebas et al: Hemofiltration in pancreatogenic sepsis1810
Fig. 1. Survival rates. The significant im-
provement of survival in hemofiltered animals
depended on the intensity of CVVH. Analysis
of survival in treatment groups revealed sig-
nificantly better results by intensifying CVVH
(filter change, increasing ultrafiltration rate).
Symbols and definitions are: () group 1, con-
trols; () group 2, late CVVH, no filter change,
20 mL/kg BW/h; () group 3, early CVVH,
no filter change, 20 mL/kg/h; () group 4, late
CVVH, filter change, 20 mL/kg/h; () group
5, early CVVH, filter change, 20 mL/kg/h; ()
group 6, late CVVH, filter change, 100 mL/
kg/h; () group 7, early CVVH, filter change,
100 mL/kg/h.
temperature were significantly delayed. CVVH signifi- concentrations was only delayed (48 hours post-induc-
tion: group 2, 162  44; group 3, 191  55 mg/L). In thecantly prolonged survival compared with untreated con-
trols. Nineteen animals (group 4, N  1; group 5, N  later phase of the experiments (36 to 60 hours post-
induction) the benefit of changing hemofilters in terms3; group 6, N  6; group 7, N  9) were still alive at the
end of the observation period (60 hours) (Fig. 1). of attenuating the CRP response became evident. At 48
hours post-induction none of the experimental groups
Occurrence of sepsis: Bacteremia and undergoing filter change (groups 4 to 7) exhibited CRP
infection of ascites levels 125 mg/L (P  0.05 vs. groups 2 and 3). Increas-
ing the filtration rate at this point of time led to furtherBlood cultures revealed bacterial growth in 73 animals,
among which a paucity of only four animals did not attenuation of the CRP response (group 6, 76 34 mg/L;
group 7, 83  26 mg/L; P  0.05 each) compared tobecome septic. Thus, a total of 69 animals became septic
in the course of experiments. The whole entity of 15 low-volume CVVH (group 4, 121  36; group 5, 113 
25 mg/L).animals that did not develop sepsis underwent intensi-
fied, high-volume CVVH, all in groups 6 and 7 (data not Urinary trypsinogen activation peptides (TAP) levels
increased from baseline values below 1.3 nmol/L to peakreported in detail). Dominance of a single species was
not found. CVVH delayed the occurrence of sepsis sig- values up to 245 nmol/L. No significant differences be-
tween the experimental groups were found.nificantly. Bacteria found in positive blood cultures had
been assessed without exception in previously sampled White blood cell (WBC) counts ranged from 6.2 1.7
to 7.8  2.0  103/L pre-induction. Animals becomingabdominal secretions. CVVH significantly reduced the
bacterial infection of ascites. In contrast, it did not influ- septic showed a biphasic pattern of leukocyte counts.
This was characterized by an initial increase of leukocyteence the coincident proof of bacterial growth in blood
cultures, once ascites were found to be infected. This counts preceding severe, leukopenia in advanced sepsis.
Changes in circulating WBC counts also occurred in mostcoincident proof of infected ascites and the identification
of identical bacteria in subsequent blood samples ranged of hemofiltered animals, although peak and nadir values
were reached significantly later (data not shown). Inter-from 52% (group 5) to 61% (group 2, NS).
estingly, none of the 15 animals that remained non-septic
Laboratory parameters developed leukopenia in the later experimental course.
Cytokines. Pancreatitis led to an initial, overwhelmingC-reactive protein, trypsinogen activation peptides, and
white blood cells. Baseline concentrations of CRP were increase of serum TNF- concentrations preceding a de-
crease to near baseline values in animals that developedbelow 10 mg/L in all groups. In controls, pancreatitis re-
sulted in a more than 25-fold increase of CRP-concentra- sepsis (Fig. 2). In groups 2, 4, and 6, due to the late be-
ginning of CVVH, the TNF- levels at 12 hours post-tions (baseline, 6.9  3.3 mg/L; 36 hours post-induction,
179  28 mg/L). CVVH weakened the CRP response induction were comparable with those in controls. In
contrast, prophylactic CVVH (groups 3, 5, and 7) attenu-distinctly. However, considerable differences between the
treatment groups were found. When filters were not ated the TNF- response as early as 12 hours post-induc-
tion. Definitive protection from restraining both the ini-changed (groups 2 and 3), the exorbitant rise of CRP-
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tial increase of serum TNF- concentrations and the final ogenous endotoxin (5 g/mL) administered via the pre-
sepsis-induced drop to baseline values was only achieved filter and detected in the postfilter line of the extra-
when CVVH was performed in a high-volume modality corporeal circuit was 95%. In addition, in none of the
(groups 6 and 7). In groups 2 and 3, the efficiency of hemofiltrate samples endotoxin was detectable. The ef-
CVVH in ameliorating the TNF- response was limited fect of CVVH in significantly attenuating endotoxemia
over time: at 36 and 48 hours post-induction the TNF- is demonstrated in Figure 3A. Later in the experimental
concentrations in groups 2 and 3 resembled those in course, high-volume CVVH was found to be significantly
controls at earlier points of time. Increasing plasma con- beneficial in restraining endotoxemia compared with
centrations of TNF- in hemofiltered animals were paral- low-volume CVVH.
leled by a significant decline of sieving coefficients (data Changes in leukocyte immunophenotypes. Endotoxin
not shown). Pearson’s correlation analysis revealed a receptor (CD14) expression on monocytes ranging from
significant reciprocal association of sieving coefficients baseline values of 74% to 81% showed a highly signifi-
with the plasma concentrations of TNF- (R  0.81, cant reciprocal correlation with plasmatic endotoxin lev-
P  0.003). els (R0.82, P 0.009). A tremendous, sepsis-induced
The late-phase decrease of TNF- levels was consis- down-regulation of CD14 expression (30%) was found
tent with in vitro experiments showing a progressive (median 26%, range 20 to 31%). In groups 2 to 5, CD14
decline of TNF- generation from endotoxin-challenged down-regulation was significantly delayed, but occurred
polymorphoneutrophils (PMNs; data not reported in de- at later points in time in a similar fashion as seen in
tail) in the course of experiments. In controls, pancreati- controls. Also, a distinct benefit of changing hemofilters
tis led to a significant decrease of TNF- generation from was found compared to animals undergoing CVVH with
371  56 pg/mL at baseline to 97  44 pg/mL 36 hours a single filter. Only in groups 6 and 7, CD14 expression 60
post-induction. Depending on the intensity of treatment, hours post-induction was still 45 and 51%, respectively.
CVVH significantly delayed (groups 2 to 5) or almost Consistent with these findings, occurrence of sepsis was
completely prevented (groups 6 and 7) this tremendous associated with a significant down-regulation of MHC
decline. At the end of the observation period, TNF- class II antigen expression (corresponding to human
release in animals treated by high-volume CVVH was HLA-DR) on monocytes (Fig. 3B). Depending on the
significantly higher than in groups 4 and 5. treatment intensity, this was effectively delayed or even
Table 4 shows that in controls, pancreatitis led to an prevented by CVVH.
enormous, primary increase of plasma concentrations of
the anti-inflammatory cytokines TGF-1 and IL-10 that Histopathology
preceded an approximation to baseline levels later in the
Pancreas. Histopathologic changes in the pancreasexperimental course. A considerable initial increase also
were found in all organ regions without predominancewas found in treatment groups. This response was signif-
for one area (head, body, tail). Irrespective of outcome,nificantly attenuated compared with controls. A biphasic
CVVH did not influence histologic changes in the pan-pattern of TGF-1 and IL-10 plasma levels also occurred
creas. The main histologic finding across groups was ain groups 2 to 5, although in a significantly delayed fash-
catastrophic, inflammatory response with extensive peri-ion, which were not definitively protected from sepsis
vascular infiltrates (mean 3.5  0.9). More moderate(data not reported in detail). Further analysis showed
scores were found for acinar necrosis (2.6  1.0) andthat the decrease of TGF-1 and IL-10 plasma levels in
edema (2.2  0.8). The only histologic finding with athe late phase of experiments was only found in animals
slight, heterogeneous distribution was fat necrosis, pre-with manifest sepsis. In contrast, in animals undergoing
dominantly localized in the pancreatic body and tail andhigh-volume CVVH with filter change, anti-inflamma-
frequently associated with foci of hemorrhage (2.0 tory cytokine levels remained moderately up-regulated
0.9). Occasionally, confluent necrotic areas were found.over the whole observation period. The assessment of
Extrapancreatic lesions. Controls and groups 2 to 5both TGF-1 and IL-10 concentrations in hemofiltrate
animals undergoing less intensive treatment modalitiesshowed an effective removal by CVVH. Surprisingly, the
showed similar severity of pulmonary and renal damage.efficiency of TGF-1 and IL-10 removal in hemofiltrate
In contrast, high-volume CVVH significantly attenuatedin contrast to that of TNF- neither depended on the
extrapancreatic histopathologic changes.filtration rate nor on filter change. This resulted in con-
Lungs. CVVH in groups 6 and 7 resulted in signifi-stant sieving coefficients of both cytokines in the course
cantly lower scores for hyaline membranes and hemor-of the experiments without any significant difference be-
rhage, respectively (P  0.05, each) compared with con-tween the treatment groups.
trols and group 2 to 5 animals (Fig. 4A). Also, group 7Endotoxemia. In preliminary experiments (N  6)
animals had a significantly lower score for microthrombiperformed to assess whether endotoxin would be filtered
or adsorbed by the filter membranes, the recovery of ex- compared with group 6 (P  0.05). The evident benefit
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Table 4. Serum (pre-/post-filter) and hemofiltrate concentrations of TGF-1 and IL-10, and resulting sieving coefficients (SC)
depending on the mode of CVVH
Serum
Group Hours Pre-filter Post-filter Hemofiltrate SC
TGF-1 pg/mL 1 0 166 — — —
2 0 1411 — — —
3 0 207 — — —
4 0 189 — — —
5 0 257 — — —
6 0 2011 — — —
7 0 1913 — — —
1 24 1309312a — — —
2 24 812202a,b 846254 423228 0.51
3 24 776186a,b 584176 374103 0.55
4 24 763238a,b 577145 402145 0.60
5 24 782221a,b 748225 436184 0.57
6 24 806312a,b 518167 364125 0.55
7 24 692231a,b 670217 395157 0.58
1 48 (no survival)
2 48 1127275a 705346 522192 0.57
3 48 1254294a 803274 504208 0.49
4 48 901305a 946284 508154 0.55
5 48 874248a 556138 429164 0.60
6 48 749218a,c,d 593195 416173 0.62
7 48 792272a,c,d 815215 475128 0.59
1 60 (no survival)
2 60 (no survival)
3 60 (no survival)
4 60 N  1
5 60 458184a 942262 378129 0.54
6 60 704178a,f 853275 436218 0.56
7 60 744214a,f 863238 458227 0.57
IL-10 pg/mL 1 0 187 — — —
2 0 2113 — — —
3 0 2512 — — —
4 0 2210 — — —
5 0 168 — — —
6 0 1311 — — —
7 0 219 — — —
1 24 32664a — — —
2 24 17363a,b 4728 6621 0.60
3 24 14758a,b 4325 5928 0.62
4 24 16174a,b 15256 8631 0.55
5 24 16063a,b 15262 9239 0.59
6 24 17757a,b 13745 9928 0.63
7 24 17951a,b 12958 9435 0.61
1 48 (no survival)
2 48 6338a 1813 2217 0.54
3 48 5527a 1411 1913 0.55
4 48 9129a 2617 3415 0.58
5 48 8336a 5031 3719 0.54
6 48 14731a,c–f 2015 4721 0.55
7 48 13639a,c–f 3421 4528 0.53
1 60 (no survival)
2 60 (no survival)
3 60 (no survival)
4 60 N  1
5 60 5126a 3722 2314 0.52
6 60 13842a,f 5438 5223 0.54
7 60 12734a,f 9532 6132 0.55
Concentrations of transforming growth factor-1 (TGF-1), and interleukin-10 (IL-10) in serum (pre-filter), post-filter, and in hemofiltrate (means  SD). Groups
are defined as: group 1, controls; group 2, “late” beginning of low-volume CVVH (20 mL/kg BW/h) without change of hemofilters; group 3, “prophylactic” CVVH
without filter change; group 4, “late” low-volume CVVH, filter change (every 12 hours); group 5, “prophylactic” low-volume CVVH, filter change; group 6, “late”
high-volume CVVH (100 ml/kg BW) filter change; group 7, “prophylactic” high-volume CVVH, filter change.
a P  0.01 vs. baseline values
b P  0.05 vs. the controls
c P  0.05 vs. group 2
d P  0.05 vs. group 3
e P  0.05 vs. group 4
f P  0.05 vs. group 5
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Fig. 2. Serum TNF- levels. The groups are
defined in the legend to Figure 1. Protection
from the overwhelming initial TNF- response
was most effective in groups 6 and 7 (high-
volume CVVH). Also, consistent with the re-
sults obtained from the measurement of TNF-
generation by endotoxin-stimulated polymor-
phoneutrophils (PMNs), the occurrence of sep-
sis was associated with a decrease of TNF-
concentrations to near baseline values. High
volume CVVH almost completely prevented
this sepsis-induced, functional loss of TNF-
generation. *P  0.05 vs. controls; †P  0.01
vs. baseline; #P  0.05 vs. group 2; §P 
0.05 vs. group 3; ‡P  0.05 vs. group 4.
of intensified CVVH in attenuating atelectasis was not human pancreatitis better than previous models. Similar-
significant. ities with the clinical situation include, in particular, the
Kidneys. High-volume CVVH mitigated significantly non-bacterial onset of the disease, the secondary bacte-
the severe tubular damage compared with groups 1 to rial translocation and endotoxemia, a hyperdynamic cir-
5 (P  0.05 vs. groups 1 to 5). Also, glomerular damage culatory response, and characteristic laboratory and im-
in group 7 tended to be less severe than in group 6 (NS) munologic derangements.
and groups 1 to 5 (P  0.05; Fig. 4B). The score incre- In a pilot study we showed that CVVH favorably in-
ments for microthrombi were attenuated by high-volume fluences several derangements found in experimental
CVVH compared to controls and groups 2 to 5 (NS). pancreatitis [6]. This previous series, which had not been
designed as a survival study, was performed to investigate
whether CVVH would have any impact on the courseDISCUSSION
of the disease. The model was eventually lethal in bothThe spontaneous course of severe, necrotizing pancre-
controls and CVVH-treated animals. Long-term survivalatitis is characterized by an initial non-bacterial (“toxic”)
and protection from sepsis did not represent primaryonset of the disease preceding secondary sepsis-related
outcome parameters.extrapancreatic complications due to the infection of ne-
In contrast, the present model, which represents acrosis. Therapeutic management in patients showing evi-
modification of the previous experimental model [6],dence of a severe course of the disease without definitive
offers a therapeutic window that provides an opportunityproof of secondary infection of necrosis is controversial.
to evaluate the impact of CVVH on sepsis protectionIt has been suggested that patients with severe pancreati-
and long-term survival as the primary target parameters.tis who seem to be at risk to develop septic complications
Continuous venovenous hemofiltration was performedmight benefit from early application of CVVH irrespec-
applying different treatment modalities. The comparisontive of the presence of acute renal failure (ARF) [23]. Con-
of periodically changing hemofilters and using one singlesequently, the impetus of applying CVVH in non-oliguric/
filter over the whole observation period served to assessanuric patients is to eliminate inflammatory mediators
whether long-term application of hemofilters results inthat are overwhelmingly released and assumed to be
decreasing efficiency of CVVH by “fouling” of mem-crucial in initiating multiorgan dysfunction.
brane pores as assumed by some authors [24]. In thisUp to now, no animal model satisfactorily reflects the
context, we particularly focused on the question whethercharacteristic biphasic course of severe pancreatitis. Le-
the removal of sepsis-related cytokines, especially that ofthality in experimental pancreatitis models is due to an
TNF-, would be compromised by long-term applicationexorbitant “toxin shock” but not to the development of
of one single filter. The impact of CVVH on serum cyto-secondary sepsis. Therefore, we established a porcine pan-
creatitis model mimicking the natural course of severe kine levels is controversial. Some investigators did not
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Fig. 3. Endotoxin concentrations (A) and
MHC II antigen expression by monocytes as-
sessed by flow cytometry (B). Groups are de-
fined in the legend to Figure 1. Attenuation
of endotoxemia was most effective in group
6 and 7 animals. Down-regulation of MHC II
expression 40% indicating severe immuno-
paralysis occurred in controls and, although
being significantly delayed, in animals not un-
dergoing filter change. By increasing the fil-
trate turnover, MHC II expression was ar-
rested at nearly control levels. There were
15,000 events per sample. *P 0.05 vs. controls;
†P  0.05 vs. baseline; #P  0.05 vs. group 2;
§P  0.05 vs. group 3; ‡P  0.05 vs. group
4; &P  0.05 vs. group 5.
detect significant decreases of inflammatory mediators in In light of these results, Ronco and coworkers therefore
recommend a filtration rate of at least 35 mL/kg BW/hthe bloodstream, although relevant concentrations were
measured in ultrafiltrate [25–27]. This may be due to the [30]. Finally, we evaluated whether “prophylactic” CVVH
prior to hemodynamic impairment would be of benefitfact that CVVH was performed with low filtration rates
and that filters were not changed. In contrast, De Vriese compared with a “therapeutic” setting started after mac-
rocirculatory deterioration. In a non-randomized trial [23],et al reported that in septic patients with ARF, cytokine
removal in the hemofiltrate is associated with a signifi- it has been hypothesized that “early” CVVH started
prior to overt ARF might result in considerable reduc-cant decrease of cytokine plasma levels. Also, there was
a close relationship of both the filtration rate and fre- tion of morbidity in patients with necrotizing pancre-
atitis.quency of filter changes with the efficiency of CVVH in
removing cytokines [28]. Other studies confirmed the The reason not to perform “late” CVVH according
to the clinical situation in humans after the occurrencebenefits of increasing the filtration rate in terms of im-
proved survival or accelerated recovery from ARF [29, 30]. of ARF was that, in minipigs, a critical perfusion pressure
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Fig. 4. Pulmonary (A) and renal (B) score
increments. Symbols and definitions are: ()
group 1, controls; () group 2, late CVVH, no
filter change, 20 mL/kg BW/h; ( ) group 3,
early CVVH, no filter change, 20 mL/kg/h; ( )
group 4, late CVVH, filter change, 20 mL/kg/h;
( ) group 5, early CVVH, filter change, 20 mL/
kg/h; ( ) group 6, late CVVH, filter change,
100 mL/kg/h; ( ) group 7, early CVVH, filter
change, 100 mL/kg/h. Significantly improved
scores for several pulmonary and renal vari-
ables were found in animals treated by intensi-
fied CVVH. Pulmonary and renal injuries in
groups 2 to 5 were comparable with those in
controls. *P  0.05 vs. groups 1 to 5; #P 
0.05 vs. group 6.
of about 40 mm Hg assessed in preliminary experiments in animals undergoing high-volume CVVH that repre-
sented the most intensified treatment modality per-was sufficient to maintain urinary output. When started
below this threshold, CVVH induced severe cardiovas- formed in this study. Most likely, this was due to a more
effective removal of sepsis mediators. Particularly, thecular depression. Therefore, “late” CVVH was started
after a decrease of TPR below a cut-off of 30% found overwhelming, initial TNF- response was distinctly sup-
pressed by CVVH. The drop of TNF- levels to nearto be the clinical variable that was best associated with
occurrence of sepsis. baseline concentrations characterizing advanced sepsis
seemed to be paradoxical as it was orchestrated by sig-Occurrence of sepsis as one of the target parameters
of the study was significantly delayed by CVVH. A pro- nificantly higher plasmatic endotoxin levels than those
in non-septic animals. Because endotoxin is known totection from sepsis over the whole observation period
was only achieved in animals undergoing high-volume be the major stimulator of TNF- release, the dissocia-
tion of final TNF- decrease and exorbitant endotoxinCVVH and filter changes. Eventually, with respect to
survival, we observed considerably improved outcome levels suggested severe immunodepression in septic ani-
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mals in terms of endotoxin hyporesponsiveness. The re- increase of both anti-inflammatory cytokines in plasma
preceding an approximation to near baseline levels insults obtained from in vitro TNF- generation by endo-
toxin-stimulated PMNs strengthened our assumption of animals that developed sepsis. Whereas the enormous,
primary response of anti-inflammatory cytokines repre-endotoxin tolerance in end-stage sepsis. Pending on its
efficacy in definitely providing sepsis-protection, CVVH sented a hyperinflammatory “pre-septic” condition, the
decrease in the further course of experiments was closelywas found to attenuate or completely prevent progres-
sive decrease of TNF- generation in endotoxin-stimu- associated with manifest sepsis. CVVH at least delayed
or even completely prevented this biphasic feature oflated PMNs.
The finding that endotoxemia was ameliorated by anti-inflammatory cytokine response that evidently pre-
dicted a deleterious septic course. Hemofiltrate concen-CVVH was of particular interest, since preliminary ex-
periments had shown that endotoxin did not pass the trations in animals undergoing high-volume CVVH were
comparable with those detected in “standard” CVVH.filters used in our setting. Consistently, endotoxin was
not detectable in any hemofiltrate sample analyzed. Nevertheless, it has to be assumed that the real amount
of TGF-1 and IL-10 removed in groups 6 and 7 wasTherefore, it seems to be conclusive that CVVH, by
stabilizing systemic hemodynamics, improves splanchnic five times higher, since the hemofiltrate volume was dif-
ferent. The proof of elevated IL-10 and TGF- levels inperfusion. Further evidence that CVVH stabilizes the
mucosal barrier and restrains bacterial translocation was serum over the whole observation period in high-volume
hemofiltered animals suggests immunomodulating ef-provided from the microbiological screening. Bacteria
assessed in positive blood cultures were without excep- fects of CVVH in terms of a beneficial arrest of moder-
ately up-regulated, anti-inflammatory cytokine synthesis.tion present in abdominal secretions. This suggested a
route of bacterial invasion from the abdominal cavity The histopathologic screening showed that the induced
pancreatic injury closely resembled that of human pan-into the bloodstream.
The distinct attenuation of sepsis-induced down-regu- creatitis. The homogenous distribution of pancreatic in-
jury across the experimental groups revealed the repro-lation of both leukocyte MHC class II and CD14 antigen
expression in treatment groups indicated that CVVH ducibility of the model. It also was evidence for the lack
of any benefit of CVVH in favorably influencing the lo-might interact with immunologic derangements found
in pancreatitis. Mononuclear MHC II expression is of cal pancreatic damage. This was consistent with the re-
sults obtained from the assessment of urinary TAP levels.crucial importance in cell-mediated initiation of the im-
mune response. Numerous studies report a down-regula- Elevated TAP concentrations in urine are a result of a
trypsinogen “burn” in the pancreas itself; this may causetion of MHC II	 leukocytes in septic diseases [31–33]. In
our series, controls and treatment groups not undergoing a devastating tryptic autodigestion of the pancreas and
the peripancreatic tissue characterizing severe necrotiz-filter changes showed a decrease in HLA-DR expression
below a threshold of 30% that is assumed to be closely ing pancreatitis. Because increased urinary TAP concen-
trations are found in severe necrotizing pancreatitis, TAPrelated with fatal immunodeficiency in severe sepsis [34].
Conflicting data exist concerning alterations of CD14 assaying is helpful in predicting the local severity of the
disease [41]. Therefore, the lack of any significant differ-endotoxin receptor expression in sepsis. McCall et al
report unchanged CD14 expression in PMNs from sepsis ence in urinary TAP concentrations between untreated
controls and either of the treatment groups demonstratedpatients [35]. However, in light of evidence suggesting
reduction of CD14 receptor density in endotoxin toler- that CVVH did not affect the focal pancreatic damage.
Extrapancreatic histologic changes in lungs and kid-ance [36], we examined the influence of CVVH on CD14
expression in monocytes. CVVH limited CD14 down- neys, in contrast, were ameliorated when animals under-
went intensified, high-volume CVVH. Less intensiveregulation as long as it prevented sepsis. This was evi-
dently due to the close reciprocal relationship of CD14 treatment modalities in groups 2 to 5 failing to provide
definitive protection from sepsis were associated withdown-regulation with the extent of endotoxemia.
The screening of IL-10 and TGF- concentrations pro- histologic changes in lungs and kidneys comparable with
those in controls. Also, a distinct benefit of “prophylac-vided further evidence for beneficial effects of CVVH
on sepsis-related immunologic alterations. Numerous re- tic” CVVH (group 7) compared with a “therapeutic”
setting (group 6) in restraining extrapancreatic alter-ports underline the role of anti-inflammatory cytokines,
particularly of IL-10, in both sepsis and pancreatitis. In ations such as pulmonary microthrombi was found.
Because acute pancreatitis is usually a self-limitingmice, the exogenous application of IL-10 has been re-
ported to prevent septic shock [37, 38] and to lower the disease not requiring interventional and/or surgical sup-
port, criteria have to be defined for clinical protocolsmortality rate [39]. In murine pancreatitis, IL-10 has
been assumed to delay the development of acinar necro- from which patients might benefit from CVVH irrespec-
tive of the presence of ARF. Pancreatitis-induced multi-sis [40]. In our series, the natural course of pancreatitis
in controls was associated with an initial, tremendous organ failure is usually due to an infection of primary
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